Axon Enterprise struggles with a 17.5% YTD decline and dilution concerns following a $1 billion convertible note offering, despite maintaining a 'Strong Buy' consensus from analysts.
AXON has fallen 40.9% from its 52-week high, is down 17.5% YTD versus Nasdaq's 11.8% gain, and faces dilution concerns from a $1 billion convertible notes offering and falling cash balance.
L3Harris is mentioned as a top rival; its stock has decreased 11.8% over 52 weeks and 14.6% YTD, performing less poorly than AXON.
Nasdaq Composite is used as a benchmark, up 11.8% YTD and 16.3% over 52 weeks, highlighting AXON's underperformance.
Axon Enterprise faces significant headwinds, with shares down 17.5% year-to-date and trading 40.9% below their 52-week high. The company's recent $1 billion convertible notes offering has sparked investor concerns regarding equity dilution, even as management seeks to bolster a cash balance that has fallen below $700 million.
Shares plunged 9.8% on September 15 following the announcement of a $1 billion offering of 0% convertible senior notes due in 2031, which raised concerns about shareholder dilution.
Axon has underperformed its rival L3Harris, with Axon down 17.5% YTD compared to a 14.6% decline for L3Harris.